Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teijin has signed an exclusive licensing agreement with SanBio, a US developer of regenerative therapies for neurological disorders, to develop and sell SB623 in Japan. SB623 is said to be promising as an effective drug for stroke therapy. Teijin has also taken an equity position in SanBio as part of the agreement.
Subscribe to our email newsletter
Based on the results of pre-clinical and clinical trials conducted by SanBio, Teijin plans to begin clinical trials in Japan.
SanBio developed SB623 by processing bone marrow from donors for introduction into the brains of stroke patients, in order to promote regeneration of damaged central nervous neuronal cells. SB623 has shown remarkable positive results in mammal animals, said the company.
Going forward, Teijin intends to expand its involvement in the regenerative market by developing medicines and treatments that improve the quality of life for people suffering from stroke and related sequelae.